INTERFERON REDUCES RECURRENCES OF BASAL CELL AND SQUAMOUS CELL CANCERS |
| |
| Authors: | DRAGO IKI&# ,M.D.,,IVO PADOVAN,M.D.,,NEDIM PIPI&# ,M.D.,,VLADIMIR &# AJKOVAC,M.D.,,ZVONKO KUSI&# ,M.D.,,NIKOLA DAKOVI&# ,M.D.,,TEODORA GREGUREK-NOVAK,M.D.,,ANTICA SOLDO-BELI&# ,M.D.,,&# IME SPAVENTI,M.D.,,MLADEN BELICZA,M.D.,,&# ELJKO FEREN&# I&# ,M.D. |
| |
| Affiliation: | Department of Medicine, Croatian Academy of Sciences and Arts, Institute for Research and Standardization of Immunologic Substances, Zagreb, Croatia, and University Hospital "Sestre Milosrdnice," Zagreb, Croatia. |
| |
| Abstract: | Background.Interferon is considered to be an important curative agent for dermatologic diseases. We report the follow-up experience of patients with basal cell or squamous cell carcinomas treated with human natural leukocyte interferon (hnli ). Results. Among 52 patients with basal cell carcinoma (bcc ) treated with hnli more than 10 years ago, and among 58 treated more than 5 years ago, only 2 recurrences were observed. There were no recurrences in 75 patients who had a complete response to hnli treatment, nor were there any in 20 patients with either a partial or complete response to r.IFM alpha 2c treatment. Of 52 patients with squamous cell carcinoma (scc ), 31 had been treated more than 10 years earlier, two recurrences of the disease at the site of the original lesion were observed. Conclusion. Interferon treatment makes it possible to achieve a persistent cure in patients with BCC and sec in a high proportion of cases. The potential advantage of nonsurgical treatment are an enhancement of cosmetic results through the prevention of destruction of important anatomic structures. |
| |
| Keywords: | |
|
|
